The aim of the research is to study the immune checkpoint linked to the HLA-G molecule in the dysregulation of the control of COVID-19 infection.
Single-center, prospective, open-ended, interventional study with minimal risks and
constraints. Patients will be divided into 3 groups: patients not infected with COVID-19,
patients infected with COVID-19 not hospitalized, patients infected with COVID-19
hospitalized.
Other: Baseline and during hospitalization blood samples
Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :
at day 3
day 5 and
In case of aggravation
At the discharge from hospital
Other: Baseline blood sample
Blood sample will be performed at the inclusion visit only
Inclusion Criteria:
- Patient with possible or confirmed infection by COVID-19
Exclusion Criteria:
- Patient without liberty or guardianship
Foch hospital
Suresnes, France
Olivier BRUGIERE, PhD, Principal Investigator
Hopital Foch